Swedish Orphan Biovitrum, the Nordic biotech company known as Sobi, has appointed Amy Pott as the new head of Sobi North America. She takes over effective today, replacing Rami Levin who is leaving Sobi.
“Sobi North America is entering a new phase in line with Sobi’s growth strategy, with the workforce growing more than fourfold in just more than a year. The launch of Gamifant [emapalumab] and the integration of Synagis are key to the company’s future and I am delighted to welcome Amy to Sobi for her to take on this challenge,” says Guido Oelkers, chief executive.
Ms Pott was most recently group vice president and US franchise head for Internal Medicine & Oncology at Shire, which has recently been acquired by Japan’s Takeda. She was also group VP for US Commercial Operations at Shire and VP of strategy, planning and analytics at Baxalta, all roles based in Boston. Prior to her roles in the USA, Ms Pott spent 10 years at Baxter, where she held UK and international roles working with both rare diseases and medical devices. During her time in the UK she built up Baxter’s UK & Ireland market access team.
Ms Pott has a strong background in private and public healthcare, having worked as an Associate for APCO Worldwide in London, Sacramento and San Francisco supporting a wide range of public sector companies. Previous to her roles at Baxter and Shire, Pott held positions at the National Institute for Health and Clinical Excellence (NICE) and the NHS Confederation. Amy Pott will be part of the Sobi executive committee.
Source: The Pharma Letter
Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash. Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.
Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.
Chinese cancer biotech Adagene has filed to raise up to $125 million in a Nasdaq IPO. The listing will give Adagene the means to run early-phase clinical trials of antibodies against CD137 and CTLA-4.